Hanako Tsuyuzaki

Highlights of our recent blog articles: ・PMDA Washington Office ・MHLW listed up 78 drugs in its wanted list ・Japanese new guidance on orphan drug development (https://idec-inc.com/blog/) Eliquent Japan is a Japanese regulatory and commercial consulting firm. We support orphan drug consultation, PMDA, the Japanese health authority, consultation and drug licensing support. (https://idec-inc.com/) #pharma #biotech #businessinsights

3

SK Biopharmaceuticals announced on December 4 that its Chinese partner, Ignis Therapeutics, will receive USD 15 million (approximately KRW 21.051 billion) in milestone technology fees for submitting a Novel Drug Application (NDA) for the epilepsy treatment 'cenobamate' to the China National Medical Products Administration (NMPA). https://lnkd.in/g_QjMk3W

1

🌟 Discover AMED's Role in Japan's Drug Discovery Future*🌟 Welcome to the first part of our 10-part series, where we explore the transformative impact of the Japan Agency for Medical Research and Development (AMED) on Japan's drug discovery landscape. 🚀 Overview of AMED 🚀 AMED, established in April 2015, is a cornerstone of Japan's efforts to advance medical research and development. By integrating efforts across the Ministry of Health, Labour and Welfare (MHLW), the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and the Ministry of Economy, Trade and Industry (METI), AMED fosters a seamless and effective approach to medical innovation. 🎯 Mission and Vision 🎯 AMED's mission is to support a continuum of research activities, from basic science to clinical application, ensuring that promising discoveries receive the necessary support to advance through the development pipeline. The agency envisions Japan as a global leader in medical innovation, contributing significantly to the advancement of healthcare through groundbreaking research and development. 🌐 Strategic Importance 🌐 AMED plays a pivotal role in shaping the future of drug discovery in Japan. Through its diverse array of programmes, including the Strengthening Program for Pharmaceutical Startup Ecosystem/Venture Capital, AMED creates a robust support system for pharmaceutical startups and venture capital firms. This initiative not only empowers startups to bring novel therapies to market but also fosters a collaborative environment where venture capital firms can invest with confidence. Join us on this journey as we delve deeper into AMED's initiatives and their impact on Japan's healthcare and biotech sectors. Stay tuned for more insights in our upcoming posts! #AMED #PharmaceuticalStartups #VentureCapital #DrugDiscovery #HealthcareInnovation #MedicalResearch #JapanInnovation #PublicPrivatePartnerships #SIIFIC #SIIFICWellnessFund https://lnkd.in/garu8uZt

5

𝐈𝐧𝐧𝐨𝐯𝐞𝐧𝐭 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐔𝐩𝐝𝐚𝐭𝐞𝐬 𝐨𝐧 𝐌𝐚𝐳𝐝𝐮𝐭𝐢𝐝𝐞'𝐬 𝐆𝐋𝐎𝐑𝐘-𝟏 𝐒𝐭𝐮𝐝𝐲 𝐚𝐧𝐝 𝐁𝐢𝐨𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 Innovent Biologics, Inc. (HKEX: 01801) Innovent Biologics provided updates on clinical data from the GLORY-1 study and its biomedicine pipeline at a recent investor call. At the 2024 American Diabetes Association (ADA) Scientific Meeting, Innovent reported results from its first Phase 3 study (GLORY-1) on the GLP-1R/GCGR dual agonist mazdutide (IBI362) in overweight or obese adults in China. The study showed significant weight reduction, liver fat reduction, and improvement in metabolic indicators, confirming mazdutide's unique advantages. CFO Rachel You Rachel You and VP of Clinical Development Lei Qian Lei Qian, along with Professor Linong Ji, provided detailed interpretations of the data. Mazdutide, an analogue of oxyntomodulin, activates both GLP-1R and GCGR, effectively reducing weight, increasing energy expenditure, burning fat, and improving liver fat metabolism. These results reaffirm the potential of new-generation GLP-1R/GCGR dual agonists in metabolic health. Innovent continues to pursue new development pathways beyond T2D and weight management, aiming to deliver transformative treatments in metabolic health. #InnoventBiologics #Mazdutide #GLORY1 #ClinicalResearch #Biomedicine #MetabolicHealth #WeightLoss #ADA2024 #HealthcareInnovation #Biopharmaceuticals

3

【Interview with Jing Zhang, CFO of 3D Medicines: Achieve Profitablity with Market Essential Demand Product Portfolio】 🚀 With the distinction of owning the world’s only subcutaneous PD-L1 injection product, 3D Medicines has maintained a gross profit margin of over 90% for years, laying a strong foundation for commercialization. However, the timeline for reaching breakeven remains a key concern for investors. 📢 Futu I&E proudly had an in-depth conversation with Jing Zhang, CFO of 3D Medicines, discussing financial performance, product R&D, and international strategy. 🔑 We’ve distilled some core insights from this conversation to share with you: 🌟 The way to maintain consistently high gross profit margins 🌟 Perspective on international market expansion 🌟 Process of managing pharmaceutical R&D effectively 👉 Please click the link to read the full article: https://lnkd.in/gyWGeSsF #Futu #Futuie #Pharmaceuticals #Innovation #Commercialization #GlobalStrategy #Biotech

2

Taiwan Life Sciences Biweekly - July 15, 2024 🔊 Foreseen Biotechnology Strikes $1.03B Deal with Ipsen SA of Paris for First-in-Class ADC 🔊 (Thailand) Saha Group collaborates with (Taiwan's) Quark Biosciences to venture into biotechnology 🔊 BIO Asia–Taiwan 2024 to Set Record, Aims to Propel Taiwanese Companies onto the International Stage, Focuses on Cell Therapy and Regenerative Medicine 🔊 Synmosa Biopharma obtains Celltrion's drug transfer rights for Taiwan and Hong Kong, completing over 20 drug license transfers 🔊 Foresee Pharmaceuticals Co., Ltd.'s New Prostate Cancer Drug CAMCEVI Receives Approval for Market in Israel 🔊 2024 Taiwan BIO Awards Announced 19 Winners: The Outstanding Company Award won by Lotus Pharmaceutical Co., Ltd, PharmaEssentia, and Bonraybio. The Emerging Company Award given to Pharmosa Biopharm Inc, TSH Biopharm Corporation Ltd, Steminent Biotherapeutics, Onyx Healthcare , and 明基透析科技. The Startup Award went to Acepodia, ImmunAdd Inc., Sunhawk Vision Biotech, Elixiron Immunotherapeutics, BioGend Therapeutics (TWSE 6733), BRAXX Biotech Co., Ltd., and Protect Biotech... 🔊 Ever Supreme Bio Technology Co., Ltd.'s World's First AI-Based CAR-T Drug Screening Approved for Clinical Trials by TFDA 🔊 Lin BioScience's Acute Leukemia New Drug LBS-007 Receives US FDA Orphan Drug Designation 🔊 Diamond Biofund Inc. Establishes European Investment Bridge, Signs MOU with French Venture Capital Fund AdBio Partners. 🔊 Exosome market rapidly growing, Taiwanese companies positioned to enter. For more details, please visit: https://lnkd.in/efTm2G4S

3

𝗔 𝗣𝗿𝗲𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗚𝗿𝗼𝘄𝘁𝗵: 𝗧𝗿𝗲𝗻𝗱𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗚𝗿𝗮𝗯 𝐒𝐚𝐦𝐩𝐥𝐞 𝗣𝗗𝗙 𝗙𝗼𝗿 𝗠𝗼𝗿𝗲 𝗗𝗲𝘁𝗮𝗶𝗹𝘀👉 https://lnkd.in/gd8Qpehq 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: • Cardinal Health • Phoenix Group • Medipal Holdings Corporation • Accredo by Evernorth • Jointown Pharmaceutical Group • Max Pharma GmbH • Sinopharm • Shanghai Pharmaceuticals Holding Co., Ltd. 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 •𝗛𝗶𝗴𝗵 𝗖𝗼𝘀𝘁 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Specialty medications are often expensive, and managing the cost burden for patients and healthcare systems is a significant challenge for specialty pharmacies. •𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗘𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁: Specialty pharmacies must navigate a complex regulatory landscape, including varying reimbursement policies, licensing requirements. •𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗣𝗮𝘆𝗲𝗿 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀: Securing reimbursement for high-cost specialty medications can be challenging, as payers often impose strict criteria and prior authorization requirements. •𝗠𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗔𝗱𝗵𝗲𝗿𝗲𝗻𝗰𝗲 𝗜𝘀𝘀𝘂𝗲𝘀: Ensuring that patients adhere to complex medication regimens is a persistent challenge. 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗕𝘆 𝗧𝘆𝗽𝗲: • Oncology • Rheumatoid Arthritis • Multiple Sclerosis • Hemophilia • Others 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: • Online Channel • Offline Channel 𝗠𝗮𝗿𝗸𝗲𝘁 𝗧𝗿𝗲𝗻𝗱𝘀 •𝗥𝗶𝘀𝗶𝗻𝗴 𝗗𝗲𝗺𝗮𝗻𝗱 𝗳𝗼𝗿 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗠𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: The increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is driving demand for specialty medications that require specialized handling and administration. •𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: Specialty pharmacies are integrating technology such as mobile apps, patient portals, and telemedicine services to enhance patient engagement, improve medication adherence, and streamline communication between patients, physicians, and pharmacists. •𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗼𝗳 𝗛𝗼𝗺𝗲-𝗕𝗮𝘀𝗲𝗱 𝗖𝗮𝗿𝗲: There is a growing trend toward delivering specialty pharmacy services directly to patients' homes, allowing for more convenient and personalized care, especially for patients requiring complex therapies like infusions. •𝗩𝗮𝗹𝘂𝗲-𝗕𝗮𝘀𝗲𝗱 𝗖𝗮𝗿𝗲 𝗠𝗼𝗱𝗲𝗹𝘀: Specialty pharmacies are adopting value-based care models, where payment is tied to patient outcomes and medication efficacy. This trend is gaining momentum as healthcare systems shift toward more outcome-driven care. #SpecialtyPharmacy #PharmacyServices #PharmaceuticalCare #SpecialtyDrugs #PharmaIndustry #PatientCare #HealthcareServices #PharmaceuticalServices #MedicationManagement #ChronicDiseaseCare

1

Hello everyone, we've posted a new article regarding an expert's insight on how to minimize the drug lag in Japan 😀 https://lnkd.in/gq-Hbqfi According to the article (Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies | Therapeutic Innovation & Regulatory Science (springer.com)) recently published by Dr. Uyama (Associate Executive Director at PMDA), understanding regional drug development strategies is key in the competitive realm of pharmaceuticals, particularly for those looking to navigate the Japanese market. A recent study comparing strategies over a decade (2012–2021) reveals stark differences in how Japanese and foreign companies approach drug development and licensing, shedding light on the “drug lag” issue. Key Insights: 1. Development Approaches: Japanese firms predominantly utilize an “only-Japan” strategy for 51.1% of products, focusing on domestic markets. Foreign firms, conversely, often adopt “Multi-Regional Clinical Trials (MRCT)” strategies for 54.9% of their products, indicating a more global outlook.  2. Licensing and Drug Lag: Japanese companies show a preference for original products with minimal drug lag when there’s “no approval in the US and EU” (59.1%). However, the figure for “license-in” products with a drug lag of ≥5 years is 52.5%. This trend is not seen in foreign companies’ products.  3. Global Collaboration: The data suggests a pressing need for Japanese firms to engage in global partnerships, especially with emerging foreign companies, to reduce drug lag by considering earlier licensing and adopting global development strategies.   These findings highlight the importance of strategic planning and partnerships in Japan for international business development professionals in the pharmaceutical sector. Embracing a global approach, including engaging in MRCTs and fostering early-stage collaborations, could be key to minimizing drug lag and maximizing market presence. 

13

[Published in April 2024] 📈 Vietnamese B2B pharmaceutical platform Buymed, known locally as Thuocsi, sees a remarkable 2x year-on-year revenue growth, hitting $76.4M in 2022 💸 Despite soaring revenues, Buymed's operating losses tripled to $15.3M due to increased administrative expenses and provisions for past obligations. 🌏 Buymed isn't just stopping at Vietnam; it's broadening its marketplace model to Cambodia and Thailand, empowering small pharmacies across Southeast Asia to access affordable drugs. 🔮 As Buymed navigates growing competition and cash flow concerns, it ventures into B2B2C franchising to enhance local drugstores' operations with advanced tech solutions. 💬 With Buymed's aggressive expansion and innovative strategies, can it redefine pharmaceutical distribution in Southeast Asia? What are the potential challenges and opportunities ahead?

1

[Clinical Trials] 09/09 ImmunityBio, Inc.'s QUILT 3.055 trial results show median overall survival of over 14 months for advanced non-small cell lung cancer patients treated with ANKTIVA and checkpoint inhibitors 09/09 GRIN Therapeutics, Inc.' phase 1b trial of radiprodil shows 86% median reduction in seizure frequency with 71% of patients experiencing more than a 50% decrease 09/09 Ultimovacs ASA announces UV1 phase II trial data showing secondary endpoint benefits in mesothelioma despite not meeting primary progression-free survival target 09/09 Immunovant Inc. reports phase 2a trial results showing 76% response rate and 56% ATD-free response rate for batoclimab in Graves' disease patients uncontrolled on antithyroid drugs same day : ( ↓ NASDAQ: IMVT | -5.97% ) 09/08 Longboard Pharmaceuticals interim results show bexicaserin achieves 57.7% median seizure reduction over 9 months in ongoing 52-week PACIFIC study evaluating developmental and epileptic encephalopathies same day : ( ↑ NASDAQ: LBPH | +1.06% ) 09/08 Summit Therapeutics, Inc.' phase III HARMONi-2 trial in lung cancer shows ivonescimab with median PFS of 11.14 months compared to 5.82 months for pembrolizumab same day : ( ↑ NASDAQ: SMMT | +44.42% ) 09/08 AstraZeneca's phase III trial of datopotamab deruxtecan shows 43% reduction in disease progression or death in TROP2-QCS biomarker positive non-small cell lung cancer patients 09/08 Janssen-Cilag S.p.A.'s phase 3 MARIPOSA study shows combination of RYBREVANT and lazertinib results in 61% survival at 3 years in advanced non-small cell lung cancer patients with EGFR mutations 09/08 HUTCHMED's FLOWERS study shows osimertinib combined with savolitinib yields deeper responses in EGFRm, MET-aberrant advanced non-small cell lung cancer patients compared to osimertinib monotherapy same day : ( - NASDAQ: HCM | 0.00% ) 09/07 Daiichi Sankyo and Merck's IDeate-Lung01 phase 2 trial shows 54.8% and 26.1% objective response rates in pretreated small cell lung cancer for 12 mg/kg and 8 mg/kg cohorts respectively [Deals] 09/09 Kissei Pharmaceutical Co Ltd and Reborna Biosciences, Inc. sign research collaboration agreement for RNA-targeting small molecule drug discovery in genetic rare diseases [Venture Capital] 09/09 Epsilogen Ltd completes £12.5 million Series B expansion financing for phase Ib trial of MOv18 IgE targeting platinum-resistant ovarian cancer View the full newsletter contents for free via the link in the comments.

6

1件のコメント

【KBIC Company Topic】 Celaid has raised 1.2 billion yen in its Series A financing round to advance HSC-based cell and gene therapies and platform Celaid Therapeutics (Celaid), a Japan-based biotech developing Hematopoietic Stem Cell (HSC) therapies, today announced that it has raised an additional 460 million yen in its Series A extension round. This round was led by The University of Tokyo Edge Capital Partners (UTEC) and OSAKA University Venture Capital (OUVC) with participation from Techno Science and Joyo Capital Partners. This brings Celaid’s total raise to approximately 1.2 billion yen which includes existing Series A funding of 500 million yen and the recent 200 million yen from the NEDO Deep Tech Startup grant. Read more: https://lnkd.in/gk3kqyz2 #kbic #fbri #kobe #kansai #japan #healthcare #lifescience #innovation #hematopoieticstemcells Celaid Therapeutics

21

Collaborative efforts revolutionize pneumococcal vaccines for global health🌍 SK bioscience Sanofi Know complete story - https://lnkd.in/dW6_-XtB Oh So Eun Kim appointed to lead Organon Malaysia, driving growth and innovation Know complete story - https://lnkd.in/dUkn8zSj Celltrion Inc’s Actemra biosimilar gains approval in Korea, broadening access🧬 Know complete story - https://lnkd.in/d-VFvi7A GI INNOVATION advances cancer therapy, aiming for breakthrough treatment🎗️ Know complete story - https://lnkd.in/dBFFX3_V #PneumococcalVaccines #OrganonMalaysia #Celltrion #Actemra #CancerTherapy #MedicalInnovation

3

Amgen is accelerating its expansion in Japan. Sales are expected to expand to 86.7 billion yen in 2023, and further sales growth is expected as shown in the table. Amgen Japan's sales are on an upward curve, from 56.3 billion yen in 2021 to 87.9 billion yen in 2023. The company expects to "achieve double-digit growth over the next three years," and the 100 billion yen (6.7 billion USD) mark is within sight. The driving force will be Teppesa, for the treatment of active thyroid eye disease, which was launched in November this year. Inactive thyroid eye disease is scheduled to be added to the indications. The drug price is high at 979,920 yen (6,653 USD), and the drug price calculation included a usefulness premium I (45%) and a marketability premium I (5%), but the premium coefficient was zero due to low disclosure of the cost of goods. The cost of treatment is estimated at about 22.5 million yen (150 thousand USD) for a course of eight doses (23 vials) for a patient weighing 60 kg. The number of patients in Japan is about 35,000.  Amgen plans to launch 12 new products and add 38 new indications by 2031. New drug development covers cardiovascular disease, cancer, bone disease, inflammation/immune diseases, and neurological diseases. The next-generation BiTE antibody Imdelltra (tarlatamab) for small cell lung cancer is scheduled to be launched next year. Migraine onset suppressant Aimovig (erenumab), osteoporosis drug Evenity (romosozumab), and psoriasis drug Otezla (apremilast) are to add pediatric indications. In obesity and type 2 diabetes, a GIPR antibody-GLP-1 peptide conjugate is in the pipeline for Phase 2.   Moderna plans to start selling a cancer vaccine in 2027 at the earliest. Clinical trials have begun for skin cancer, and the company will develop the Japanese market as the first cancer-related product using mRNA technology. Moderna's cancer vaccine uses genetic testing to examine the complex changes in cancer cell markers, and artificially creates cancer markers tailored to each individual using mRNA. Multiple markers made with mRNA are administered to patients as a vaccine, allowing immune cells to recognize the markers and attack cancer cells scattered throughout the body. Moderna is jointly developing a cancer vaccine to treat melanoma with MSD. The vaccine will be used in combination with Keytruda. Clinical trials are already underway, and this combination showed a longer survival time and a significantly reduced risk of recurrence. In addition to Europe and the US, Japan was also included in the pivotal clinical trials. They believe the drug can be introduced to the market in 2027. Moderna is conducting clinical trials for lung cancer, kidney cancer, and other cancers as well. BioNTech is also developing a cancer vaccine jointly with Genentech and confirmed its safety and extended survival time in pancreatic cancer.  The market size of treatments using mRNA technology is expected to reach about 68 billion dollars by 2030.

16

This $66m oversubscribed series B for ShiraTronics, Inc. brings the yearly subtotal raised in #neuromodulation to $618 million. That's +10% on this time last year, and a significant increase on the 2022 numbers. Yes, in many ways, and for many reasons this has been a challenging year, however you can't ignore this continued, and increasing interest in #neurotech from investors. Any start-ups in this space currently raising, or planning to raise should be encouraged by these stats. IMO there is no other area of #medtech that comes close to the sheer potential that Neuromod presents. Norwest Venture Partners led this investment round, and Shiratronics will use the funds to support their recently launched pivotal trial "RELIEV-CM2” to evaluate their Migraine Therapy System. The fnancing is also intended to fund initial commercial launch as they seek FDA PMA. Big congratulations to Rob Binney and the Shiratronics gang. UPDATED: Just seen a $27m raise from Nyxoah too. That's some 24hrs for Neuromod. Congratulations all

53

1件のコメント

What’s the challenge of business development for Taiwan biotech company？The first challenge is corporate awareness, even it’s public listed with hundred billions capital size in Taiwan , but is still no awareness in global pharmaceutical market. You are nobody out of Taiwan. The second is less global BD talent in Pharma industry. Especially not familiar in licensing-out business due to limited experience in past decades. The third is weak international networks to foster connections, the main reason is no affiliate or branch in US or EU. And the fourth is not to know global marketing. The last and critical challenge is top management concept and mindset. The long term and comprehensive planning with talent and strategy is needed , however, usual less foresight and just think how to pleased investors.

19

1件のコメント

Taiwan Life Sciences Biweekly - Dec. 9, 2024 📣 PhytoHealth Corporation 懷特生技新藥 's cancer fatigue drug which has been included in Taiwan's National Health Insurance (NHI) coverage since March 2021, recently released its first real-world evidence RWE data: 91 percent of patients showed improvements. 📣 BIONET Therapeutics, a subsidiary of the BIONET Group (TW: 1784), to debut on Emerging Stock Market, leveraging exosome and AI technologies to target regenerative medicine market 📣 Sun Ten Pharmaceutical Co., Ltd.'s NRICM101 COVID-19 treatment receives prescription drug approval in Taiwan. 📣 Lin BioScience's new drug LBS-007, developed for the treatment of acute myeloid leukemia (AML) undergoes expedited review in the US 📣 Formosa Pharmaceuticals, Inc. and Medvisis Switzerland agree on commercialise clobetasol propionate ophthalmic suspension for post-operative eye pain therapy 📣 Foresee Pharmaceuticals' new formulation drug CAMCEVI 42 mg prolonged-release suspension for injection, developed for treating advanced prostate cancer in adults, receives UK approval. 📣  In HIMSS24 APAC Seoul, Healthcare Conference & Exhibition, Taiwan's Award-Winning China Medical University Hospital (CMUH) established international presence with four notable gradings, leading Taiwan's Smart Healthcare Transformation. 📣 AmCad BioMed launches EU and Middle East operations, Puriblood enters Brazil. 📣 Andros Pharmaceuticals Co. Ltd' topical anesthetic compound ointment approved for market launch by TFDA 📣 TaiMed Biologics' long-acting HIV drug Phase IIa trial results expected soon To Read More: https://lnkd.in/g264C-Wc

7

Pharmaceutical Giants Takeda, Astellas, and SMBC Launch Joint Venture to Boost Early-Stage Drug Discovery in Japan Takeda, Astellas Pharma, and Sumitomo Mitsui Banking Corporation have formed a joint venture in Japan to support early-stage pharmaceutical discovery programs and foster innovation in therapeutics. The venture, led by Toshio Fujimoto, will be based in Fujisawa and will focus on advancing drug discovery technologies, supporting entrepreneurship, and increasing the capacity to generate high-quality startup companies. Takeda and Astellas will contribute their expertise to the venture, with the ultimate goal of introducing groundbreaking therapeutics to the market. For more details please click the link! https://lnkd.in/d_t5pFCf #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

2